Results from our Phase 1 clinical trial have been published in Nature Portfolio's Nature Medicine. This publication highlights the potential of our novel immunotherapy combination, botensilimab plus balstilimab, for treating microsatellite stable metastatic colorectal cancer (MSS mCRC), a cancer type historically resistant to immunotherapy. Read the full publication here: https://lnkd.in/ernW76JY
About us
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us at @agenus_bio. Our Community Guidelines are available at our website and at: https://agenusbio.com/community-guidelines/
- Website
-
https://agenusbio.com/.
External link for Agenus
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Lexington, Massachusetts
- Type
- Public Company
- Founded
- 1994
- Specialties
- Immuno-oncology, Cancer Vaccines, Checkpoint Inhibitors and Modulators, Immunotherapy, Cell therapy, Antibodies, and GMP Manufacturing
Locations
-
Primary
3 Forbes Road
Lexington, Massachusetts 02421, US
Employees at Agenus
Updates
-
Yesterday, our Chief Medical Officer, Dr. Steven O'Day, joined clinical experts and researchers at Nature Portfolio’s Cancer Immunotherapy conference in Boston, where he shared the latest data and insights from our botensilimab programs. Thank you to all participants for the impactful discussion as we work together to advance the field of immunotherapy.
-
-
Tomorrow, Agenus is participating in the Goldman Sachs 45th Annual Global Healthcare Conference. Join our Chairman & CEO, Garo Armen, and Chief Commercial Officer, Robin Taylor, for a fireside chat on June 12th at 8:00 a.m. ET. Register for the live webcast: https://lnkd.in/eid_skwx
-
Agenus' own Dr. Steven O'Day will be speaking at the Nature Portfolio event "Cancer Immunotherapy: From Bench to Bedside and Back," presenting an update on our botensilimab programs. Learn more here: https://lnkd.in/eFMJeAJW
-
Congratulations to Dr. Pashtoon Kasi on receiving the Yvonne Award from OncoDaily last Friday at #ASCO24. The award, for “Challenging the Status Quo,” recognizes leaders advancing cancer care and celebrates innovation in the field. Dr. Kasi exemplifies this innovation by leading the NEST clinical trials of botensilimab/balstilimab in neoadjuvant colorectal cancer.
-
-
Yesterday, Dr. Marwan Fakih shared an analysis from our botensilimab/balstilimab MSS colorectal cancer program at #ASCO24. Learn more about BOT/BAL’s activity in difficult-to-treat metastatic sites of disease in the presentation: https://bit.ly/4bJJ2OY
-
-
Are you a physician attending #ASCO24? Join us in Chicago to discuss the future of immuno-oncology with our Medical Affairs team. Schedule a meeting here: https://lnkd.in/ewFuK48r
-
-
As #CancerResearchMonth nears a close, Dr. Benny Johnson shares his insights on the importance of innovative immunotherapy treatments in improving outcomes and enhancing quality of life for individuals living with cancer.
-
Agenus is headed to #ASCO24 where Dr. Marwan Fakih will share a new analysis that highlights botensilimab/balstilimab’s activity across challenging metastatic disease sites in MSS colorectal cancer. Learn more about the data and upcoming presentation: https://bit.ly/452JyoS
-